Circulating tumor cells in breast cancer: A tool whose time has come of age

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Swaby, Ramona F ^a   Cristofanilli, Massimo ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; BREAST CANCER; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DIAGNOSTIC VALUE; DISEASE MARKER; EPITHELIUM CELL; GENOTYPE; HUMAN; MESENCHYME CELL; METASTASIS; OVERALL SURVIVAL; PHARMACODYNAMICS; PHENOTYPE; PROGNOSIS; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; SHORT SURVEY; THROMBOEMBOLISM; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; BREAST TUMOR; CYTOLOGY; DRUG MONITORING; FEMALE; MEDICAL RESEARCH; METHODOLOGY; PATHOLOGY; REVIEW; STANDARD; TUMOR EMBOLISM;

BIOMEDICAL RESEARCH; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYTOLOGICAL TECHNIQUES; DRUG MONITORING; FEMALE; HUMANS; NEOPLASTIC CELLS, CIRCULATING;

EID: 79954585183     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-43     Document Type: Short Survey

References (38)

1. American Cancer Society Cancer Fact & Figures 2009. 2009, American Cancer Society., http://www.cancer.gov
2. National Cancer Institute Surveillance Epidemiology and End Results (SEER) Cancer survival statistics. National Cancer Institute Surveillance Epidemiology and End Results (SEER)., http://seer.cancer.gov/statistics
3. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005, 5:591-602. 10.1038/nrc1670, 16056258.
4. Honig SF. Treatment of metastatic disease. Disease of the Breast 1996, 669-734. Philadelphia, PA: Lippincott-Raven, Harris JR, Lippman ME, Morrow M, et al.
5. Recamier JCA. L'histoire de le Meme Maladie. Gabor 1829, 110.
6. Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Australian Med J 1869, 14:146.
7. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis - clinical applications. 2010, 7(12):693-701. Epub 2010 Oct 19.
8. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH-F, Norton L, Massague J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326. 10.1016/j.cell.2009.11.025, 2810531, 20064377.
9. Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002, 25:104-110.
10. Kagan M, Diamandis EP, Fritsche HA, et al. Tumor markers: physiology, pathobiology, technology and clinical applications. 2002, 405-409. Washington, D.C.: AACC Press.
11. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A, Maes H, Huget P, van Dam P, Vermeulen PB, Dirix LY. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. British J of Cancer 2010, 102:276-284.
12. Dotan E, Cohen SJ, Alpaugh KR, Merepol NJ. Circulating tumor cells: evolving evidence and future challenges. The Oncologist 2009, 14:1070-1082. 10.1634/theoncologist.2009-0094, 19897536.
13. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Clin Cancer Res 2007, 13:920-928. 10.1158/1078-0432.CCR-06-1695, 17289886.
14. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LWMM, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-789. 10.1056/NEJMoa040766, 15317891.
15. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Allard WJ, Doyle GV, Terstappen LWMM. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218-4224. 10.1158/1078-0432.CCR-05-2821, 16857794.
16. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LWMM. J Clin Oncol 2005, 23:1420-1430. 10.1200/JCO.2005.08.140, 15735118.
17. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M. Cancer 2008, 113:2422-2430. 10.1002/cncr.23852, 18785255.
18. Giordano A, Giuliano M, Jackson S, Reuben JM, De Laurentiis M, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Horotobagyi GN, Cristofanilli M. Circulating tumor cells (CTCs) in metastatic breast cancer: Prognosis, molecular subtypes and metastatic sites. 2011,
19. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LWMM, Hayes DF. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409. 10.1158/1078-0432.CCR-05-1769, 17085652.
20. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging?. J Clin Oncol 2008, 26:712-720. 10.1200/JCO.2007.13.8412, 18258978.
21. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O, Puccini G, Pisani P, Poli M, Dani D, Landucci E, Mariani G, Conte PF. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000, 1:156-161. discussion 162-163, 10.3816/CBC.2000.n.014, 11899654.
22. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005, 46:1144-1150.
23. Couturier O, Jerusalem G, N'Guyen JM, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006, 12:6437-6443. 10.1158/1078-0432.CCR-06-0383, 17085657.
24. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009, 27:3303-3311. 10.1200/JCO.2008.19.4423, 19451443.
25. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncol 2010, 21:33-39.
26. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 2009, 113:501-507. 10.1007/s10549-008-9951-2, 18327638.
27. Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, Handy B, Reuben JM, Cristofanilli M. Circulating tumor cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. British J Cancer 2009, 101:1813-1816.
28. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002, 6:399-404. 10.1016/S1367-5931(02)00336-8, 12023122.
29. Palumbo JS, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96:3302-3309.
30. Palumbo JS, et al. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 2008, 6:812-819. 10.1111/j.1538-7836.2008.02938.x, 18315549.
31. Akl EA, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev; CD006652 2007,
32. Zielinski CC, Hejna M. Warfarin for cancer prevention. N Engl J Med 2000, 342:1991-1993. 10.1056/NEJM200006293422612, 10874070.
33. Fuster MM, Brown JR, Wang L, Esko JD. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res 2003, 63:2775-2781.
34. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LWMM, Lane N, Wang J, Uhr J. uPar and HER-2 gene status in individual breast cancer cells from blood and tissues. PNAS 2006, 46:17361-17365.
35. Atkas B, Tewes M, Fehm T, Hauch S, Kimming R, Kasmie-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009,
36. Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrad YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ. Monitoring drug-induced H2Ax as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010, 16:1073-1083. 10.1158/1078-0432.CCR-09-2799, 2818670, 20103672.
37. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645. 10.1158/1078-0432.CCR-09-2042, 20406831.
38. S0500 A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment. A trial of the Southwest Oncology Group S0500., http://www.swog.org/